NX-2127
NX-2127 is an orally bioavailable BTK inhibitor that degrades mutant BTKC481S and the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) . It demonstrates potent antiproliferative effects in B-cell lymphoma models and has immunomodulatory activity, enhancing T-cell activation and IL-2 production in vitro.
Product Specifications
CAS Number
2416131-46-7
Product Name Alternative
BTK, NX 2127, NX2127, NX-2127
Field of Research
Cardiovascular Research, Immunology & Inflammation, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.11% (May vary between batches)
Solubility
2% DMSO+40% PEG300+5% Tween 80+53% Saline:3 mg/mL (4.17 mM) ; DMSO:150 mg/mL (208.38 mM)
Smiles
O=C1C=2C (C (=O) N1C3C (=O) NC (=O) CC3) =CC=C (C2) N4C[C@H] (CN5CCC (CC5) C6=CC=C (NC=7C (C (N) =O) =NC=C (N7) N8CCCCC8) C=C6) CC4
Molecular Formula
C39H45N9O5
Molecular Weight
719.83
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Explore Other Products
Browse additional items from our catalog
METTL17 Antibody - C-terminal region : HRP (ARP70850_P050-HRP)
IGKV3D-34 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
